Arcellx

Autologous CAR‑T therapies command very high per‑patient prices in the United States. Reference points include Carvykti around 465,000 dollars and Abecma typically in the 420,000 to 440,000 dollar range.

In practice, payers tolerate these levels when outcomes are transformative, but list‑price expansion headroom is modest and subject to value frameworks and contracting. Anito‑cel’s ability to capture value will be driven more by capacity, label expansion and share capture than price hikes.